Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure (DANISH)
Source: View publication →
In patients with nonischemic systolic heart failure, prophylactic ICD implantation significantly reduced sudden cardiac death but did not significantly improve overall survival compared to usual clinical care.
Key Findings
Study Design
Study Limitations
Clinical Significance
The DANISH trial fundamentally challenged the routine, universal use of primary prevention ICDs in all patients with nonischemic HFrEF. By demonstrating that an ICD halves sudden cardiac death but fails to significantly reduce all-cause mortality in an era of highly effective background medical therapy and CRT, it highlighted the competing risk of death from progressive pump failure and non-cardiac causes. The findings have prompted a paradigm shift toward individualized shared decision-making, emphasizing that younger patients with fewer comorbidities are more likely to realize a survival benefit from an ICD, whereas older, frailer patients may not.
Historical Context
Prior to the DANISH trial, the mortality benefit of implantable cardioverter-defibrillators (ICDs) for primary prevention was firmly established in patients with ischemic cardiomyopathy (e.g., MADIT-II). While the landmark SCD-HeFT trial also included patients with nonischemic etiology, subgroup analyses from that trial and the DEFINITE trial showed borderline or non-significant mortality benefits for the nonischemic population. Consequently, guidelines broadly recommended ICDs for both ischemic and nonischemic HFrEF patients, largely extrapolating from ischemic data. Over the subsequent decade, background medical therapy for heart failure improved significantly, and the use of cardiac resynchronization therapy (CRT) became widespread. The DANISH trial was initiated to evaluate the efficacy of primary prevention ICDs in a contemporary, strictly nonischemic heart failure population optimized on modern guideline-directed therapies.
Guided Discussion
High-yield insights from every perspective
How does the pathophysiology of sudden cardiac death differ between ischemic and nonischemic cardiomyopathy, and why might an implantable cardioverter-defibrillator (ICD) be less effective in improving overall survival for the nonischemic population?
Key Response
Ischemic cardiomyopathy often features a distinct fibrotic scar from prior infarction that serves as an anatomic substrate for fatal reentrant ventricular tachyarrhythmias. In contrast, nonischemic cardiomyopathy has a more heterogeneous pathophysiology (diffuse fibrosis, toxic, genetic) where death is more frequently due to progressive pump failure. Therefore, while an ICD successfully aborts sudden arrhythmic death, these patients often still die from progressive heart failure, preventing a significant improvement in overall all-cause mortality.
A 72-year-old patient with nonischemic cardiomyopathy (LVEF 30%) on optimal guideline-directed medical therapy presents to your clinic. Based on the DANISH trial, how should you counsel this patient regarding the risks and benefits of a primary prevention ICD?
Key Response
The resident should recognize that DANISH showed no overall survival benefit for prophylactic ICDs in nonischemic cardiomyopathy, particularly in older patients. Counseling must involve shared decision-making, explaining that while the device halves the risk of sudden cardiac death, it does not prevent death from progressive heart failure or non-cardiac age-related causes. For a 72-year-old, competing risks of mortality are high, making an all-cause survival benefit from the ICD unlikely.
The DANISH trial demonstrated an age-dependent effect of ICD implantation, with a potential all-cause mortality benefit in younger patients (under 68 years) but not older patients. How do competing risks explain this finding, and how does the high baseline rate of Cardiac Resynchronization Therapy (CRT) in this trial affect generalizability?
Key Response
Competing risks, such as non-cardiac death and progressive pump failure, increase significantly with age, diluting the mortality benefit of preventing sudden cardiac death in older adults. Furthermore, 58 percent of patients in DANISH received a CRT device (CRT-P or CRT-D). Because CRT itself induces reverse remodeling, improves left ventricular function, and reduces both sudden and non-sudden death, this high baseline utilization likely lowered the overall risk of sudden cardiac death, making the incremental benefit of an ICD much harder to prove than in older trials.
The DANISH trial challenged a long-held dogma that all patients with LVEF under 35 percent should receive an ICD. How do we synthesize the negative primary outcome of DANISH with the positive outcomes of older landmark trials like SCD-HeFT to teach trainees about the evolution of optimal medical therapy?
Key Response
Attending physicians must emphasize that baseline risk changes as medical therapy evolves. SCD-HeFT was conducted before the widespread use of modern guideline-directed medical therapy and CRT. Modern therapies (e.g., ARNIs, SGLT2 inhibitors, MRAs) have drastically reduced the background rate of both sudden and non-sudden cardiac death. DANISH perfectly illustrates the teaching point that as foundational medical therapy improves, the absolute risk reduction provided by device therapies diminishes, necessitating highly individualized, risk-stratified shared decision-making rather than blanket recommendations.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The DANISH trial was powered for a primary outcome of all-cause mortality, but the observed event rate was lower than anticipated due to modern background therapies. How does this lower-than-expected event rate impact the statistical power, and what alternative time-to-event models would better isolate the ICDs effect in the presence of competing risks?
Key Response
Lower event rates reduce statistical power, increasing the risk of a Type II error (failing to detect a true, modest difference in all-cause mortality). While the prespecified subgroup analysis suggested a benefit in younger patients, underpowered subgroups are prone to multiplicity and false conclusions. A rigorous methodological critique would advocate for the use of competing risk frameworks, such as the Fine-Gray model, to appropriately evaluate the cumulative incidence of sudden cardiac death versus death from worsening heart failure, providing a more accurate estimation of the ICDs specific treatment effect.
From an editorial perspective evaluating trial integrity, what are the primary threats to internal validity in the DANISH trial regarding the open-label design and crossover rate, and how might these factors bias the hazard ratio for the primary endpoint?
Key Response
An editor would flag that in an unblinded device trial, crossover from the control arm to the active treatment arm is a major threat. In DANISH, approximately 5 percent of the control group eventually received an ICD. In a standard intention-to-treat analysis, this crossover dilutes the treatment effect, biasing the hazard ratio toward the null (1.0). A thorough peer review would demand robust per-protocol or as-treated sensitivity analyses to ensure that this crossover did not mask a true mortality benefit.
Current heart failure guidelines historically gave a Class I recommendation for ICDs in nonischemic cardiomyopathy based on older data. How does the DANISH trial influence the strength of recommendation and level of evidence for primary prevention ICDs in updated guidelines, particularly regarding the incorporation of patient age?
Key Response
The committee must weigh DANISH against older positive trials and meta-analyses. Because DANISH showed a significant reduction in sudden cardiac death and a likely survival benefit in younger patients, completely removing the ICD recommendation is unjustified. However, DANISH provides high-quality evidence (Level A) to support downgrading the routine primary prevention recommendation in nonischemic cardiomyopathy to a Class IIa (as reflected in updated ESC guidelines). The guidelines must now explicitly incorporate age, life expectancy, and comorbidities into the recommendation algorithms, acknowledging that the incremental survival benefit over modern quadruple therapy is attenuated.
Clinical Landscape
Noteworthy Related Trials
MADIT-II Trial
Tested
Implantable cardioverter-defibrillator (ICD)
Population
Patients with prior myocardial infarction and LVEF <= 30%
Comparator
Conventional medical therapy
Endpoint
All-cause mortality
DEFINITE Trial
Tested
Implantable cardioverter-defibrillator (ICD)
Population
Patients with non-ischemic dilated cardiomyopathy, LVEF < 36%, and premature ventricular complexes or nonsustained ventricular tachycardia
Comparator
Standard medical therapy
Endpoint
All-cause mortality
SCD-HeFT Trial
Tested
Implantable cardioverter-defibrillator (ICD) or Amiodarone
Population
Patients with NYHA class II or III heart failure and LVEF <= 35% (ischemic and non-ischemic)
Comparator
Placebo
Endpoint
All-cause mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis